Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Nov 2024

Teppala Srinivas, Scuffham Paul, Edmunds Kim, Roberts Matthew J, Fairbairn David, Smith David P, Horvath Lisa, Tuffaha Haitham

Abstract excerpt

OBJECTIVES: Patients with metastatic prostate cancer (mPCa) with BReast CAncer gene (BRCA) mutations benefit from targeted treatments (eg, olaparib). In addition, family members of affected patients have increased risk of hereditary cancers and benefit from early detection and prevention. International guidelines recommend genetic testing in mPCa; however, the value for money of testing patients with mPCa and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Australia
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Germ-Line Mutation

Share to Markov Chains

Share to Neoplasm Metastasis

Share to Prostatic Neoplasms

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 38977196
DOI: 10.1016/j.jval.2024.06.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers.PMID 38977196Read ↗

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancerSemantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

Economic evaluation of extended panel analysis in cancer patients with historical NHS diagnostic germline genetic testing - A modeling study based on real-world data.Semantic proximity Read ↗

Cost-effectiveness of testing for breast cancer susceptibility genes.Semantic proximity Read ↗

A cost analysis of a cancer genetic service model in the UKSemantic proximity Read ↗

A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathySemantic proximity Read ↗

Genetic testing and economic evaluations: a systematic review of the literature.Semantic proximity Read ↗

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.Semantic proximity Read ↗

Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.